Recent report showing efficacy of SHK to human promyelocytic leukemia cells by interacting with thioredoxin reductase may promise efficacy of SHK to human hematopoietic tumors, not only myeloma cells, through multiple activities. The gene discussed is SHPK; the disease is acute promyelocytic leukemia.